This trial is evaluating whether Acalabrutinib will improve 2 primary outcomes and 16 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of up to 30 days after the last dose of study treatment or until resolution of toxicity to grade 1 or baseline, whichever occurs last up to 5 years.
This trial requires 41 total participants across 1 different treatment group
This trial involves a single treatment. Acalabrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"A large proportion of lymphomas occur in people who have neoplastic lymphoreticulous cells in their bone marrow, spleen, peripheral blood or lymphoid tissue that can be regarded as precursors of lymphocytes." - Anonymous Online Contributor
"The estimates of incidence of lymphoma, in particular, MCL, are of great interest. It seems that the number is decreasing, but it remains unacceptably high, particularly among people under the age of 50 years." - Anonymous Online Contributor
"There is no known cure and no specific treatment for mantle-cell lymphoma. This may be due to the large number of lymphomas that have not been studied and [the low survival of this type of lymphoma when it does occur (see overall survival table above)]. As a result, there are few clinical trials with mantle-cell lymphoma. If you are seeking information about lymphoma power makes it easy to find clinical trial options specific to your condition, treatment, and location." - Anonymous Online Contributor
"Lymphoma can manifest as enlargement of the lymph nodes. Asymmetrical enlargement, which may contain hard tissue, is most often seen. The enlargement may also be more prominent in the neck. Lymphoma can present as a new rash or hair loss. The skin, especially the face, may be flushed in color. The skin may be painful to the touch or to the touch. The scalp may become itchy. Fever is common in lymphoma. Lymphoma can also cause swelling in the abdomen. Symptoms including low white blood count, blood dyscrasias, and low red blood cell level are also seen in the early stages of lymphoma." - Anonymous Online Contributor
"Lymphoma, mantle-cell is a malignant lymphoma involving B-cells with the hallmark features of Hodgkin lymphocytes, follicular dendritic cells and Reed-Sternberg cells. Lymphoma, mantle-cell accounts for about 10% of all non-Hodgkin lymphomas. It frequently involves the liver and, to a lesser extent, the skin, brain and bone marrow. The prognosis is excellent but long-term survival is not exceptional." - Anonymous Online Contributor
"Patients diagnosed with large cell lymphoma (MCL) have a poor prognosis, and, therefore, have been treated primarily through the use of high-dose chemotherapy. We present a case wherein the disease progressed following a brief course of HDC with autologous stem cell transplantation. This patient has relapsed after a subsequent course of HDC/ALLRT chemotherapy. This case highlights the need for a careful assessment of the patient's disease status as part of the therapeutic dilemma that must be resolved when patients are diagnosed with large cell lymphoma." - Anonymous Online Contributor
"Acalabrutinib is a novel FDA-approved inhibitor of the Bruton's tyrosine kinase (BTK) pathway, which plays a crucial role in the B-cell receptor (BCR) signaling pathway. Thus, acalabrutinib is a promising treatment option for patients with mantle-cell lymphoma (MCL), follicular lymphoma (FL), [b-cell lymphoma] of the diffuse form and for patients resistant to standard immunotherapy." - Anonymous Online Contributor
"A substantial proportion of people treated for mantle cell lymphoma with AC will require cessation of the drug due to adverse events (AEs). However, a substantial proportion of the patients will experience a benefit response, allowing them to continue a regimen with an additional benefit while adhering to the recommended dosing intervals, resulting in a manageable risk to benefit ratio." - Anonymous Online Contributor
"The development of targeted therapies, combining chemotherapy and antibody and protein-tyrosine kinase inhibitors have improved the outcome of patients with refractory or relapsed mantle-cell lymphoma. A combination of bortezomib with rituximab has been shown to be successful at inducing long-term survivorship in both in vivo and in vivo phase 2 trial studies; however, a phase 3 clinical trial is ongoing. Novel anti-PD-L1 antibodies, tislelizumab and nivolumab, have shown very good evidence of response in mantle-cell lymphoma on preclinical studies; however, there is insufficient data to date to support their introduction in the clinic." - Anonymous Online Contributor
"Only a very small number of patients develop SLL, mantle-cell lymphoma, or peripheral T-cell lymphoma. Of these patients, the risk was significantly higher after the diagnosis of SLL. Lymphoid follicular and non-Hodgkin's lymphomas are the most common types. The incidence of T-cell lymphoma was extremely low, and the long-term prognosis was good in most patients: no deaths due to complications were recorded in patients with newly detected disease. The risk of lymphoma development in the general population is low and does not seem to depend on age." - Anonymous Online Contributor
"Acalabrutinib is well tolerated in patients with mantle cell lymphoma. Common somatic adverse events with acalabrutinib included headache, nausea, gastrointestinal adverse events (e.g., nausea, vomiting, anorexia, dyspepsia), and fatigue. Severe adverse events were rare." - Anonymous Online Contributor